CLN2 Batten Disease Update from Tern Therapeutics

More positive news for our CLN2 community this week, with Tern Therapeutics announcing that its investigational gene therapy, TTX-381, for the treatment of ocular manifestations of CLN2 disease, has been selected by the FDA to participate in the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program. TTX-381 already holds Regenerative Medicine Advance Therapeutics (RMAT) and Fast Track designations, and this new selection will help Tern work closely with the FDA to speed manufacturing readiness and support earlier patient access.